1
|
Assessment of the Potential Health Risk of Gold Nanoparticles Used in Nanomedicine. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2022; 2022:4685642. [PMID: 35936220 PMCID: PMC9355778 DOI: 10.1155/2022/4685642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/24/2022] [Revised: 06/30/2022] [Accepted: 07/12/2022] [Indexed: 11/30/2022]
Abstract
Due to unique properties, nanoparticles (NPs) have become a preferred material in biomedicine. The benefits of their use are indisputable, but their safety and potential toxicity are becoming more and more important. Especially, excessive production of reactive oxygen species (ROS) induced by the strong oxidation potential of metal NPs could evoke adverse effects associated with damage to nucleic acids, proteins and lipids. Our study gives a view on the potential cytotoxicity of gold NPs (Au NPs) of different size from the perspective of the redox state of healthy (HEK 293 T) and cancer (A375 and A594) cell lines. These cells were incubated in the presence of two concentrations of Au NPs for 24 h or 72 h and total antioxidant capacity, 8-isoprostane, and protein carbonyl levels were determined. Furthermore, the activity of antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, and catalase was detected in cell lysates. Our results compared to the results of other laboratories are very contradictory. The outcomes also differ between healthy and cancer cell lines. However, there are certainly changes in the activities of antioxidant enzymes, as well as the damage to biological molecules due to increased NP-induced oxidative stress. But the final decision of the effect of Au NPs on the oxidative state of selected cell lines requires further research.
Collapse
|
2
|
Polymeric Nanoparticles: Exploring the Current Drug Development and Therapeutic Insight of Breast Cancer Treatment and Recommendations. Polymers (Basel) 2021; 13:polym13244400. [PMID: 34960948 PMCID: PMC8703470 DOI: 10.3390/polym13244400] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 12/10/2021] [Accepted: 12/12/2021] [Indexed: 02/06/2023] Open
Abstract
This manuscript aims to provide the latest update on polymeric nanoparticle drug delivery system for breast cancer treatment after 2015 and how research-oriented it is based on the available research data. Therefore, the authors have chosen breast cancer which is the most frequent and common reason for mortality in women worldwide. The first-line treatment for breast cancer treatment is chemotherapy, apart from surgery, radiation and hormonal therapy. Chemotherapy is associated with lesser therapeutics and undesirable side effects and hence. In addition, drug resistance affects the therapeutic dose to the target site. Although various nano-based formulations have been developed for effective treatment, the polymeric nanoparticles effectively avoid the lacunae of conventional chemotherapy. There has been an effort made to understand the chemotherapy drugs and their conventional formulation-related problems for better targeting and effective drug delivery for breast cancer treatment. Thus, the polymeric nanoparticles as a strategy overcome the associated problems with resulting dose reduction, enhanced bioavailability, reduced side effects, etc. This present review has compiled the research reports published from 2015 to 2021 from different databases, such as PubMed, Google Scholar, ScienceDirect, which are related to breast cancer treatment in which the drug delivery of numerous chemotherapeutic agents alone or in combination, including phytoconstituents formulated into various polymer-based nanoparticles.
Collapse
|
3
|
Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2021. [DOI: 10.1007/s40005-021-00532-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
4
|
The Effect of Selenium Nanoparticles on the Osteogenic Differentiation of MC3T3-E1 Cells. NANOMATERIALS 2021; 11:nano11020557. [PMID: 33672352 PMCID: PMC7926403 DOI: 10.3390/nano11020557] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/16/2021] [Revised: 02/10/2021] [Accepted: 02/17/2021] [Indexed: 12/13/2022]
Abstract
Reactive oxygen species (ROS) regulate various functions of cells, including cell death, viability, and differentiation, and nanoparticles influence ROS depending on their size and shape. Selenium is known to regulate various physiological functions, such as cell differentiations and anti-inflammatory functions, and plays an important role in the regulation of ROS as an antioxidant. This study aims to investigate the effect of selenium nanoparticles (SeNPs) on the differentiation of osteogenic MC3T3-E1 cells. After fabrication of SeNPs with a size of 25.3 ± 2.6 nm, and confirmation of its oxidase-like activity, SeNPs were added to MC3T3-E1 cells with or without H2O2: 5~20 μg/mL SeNPs recovered cells damaged by 200 μM H2O2 via the intracellular ROS downregulating role of SeNPs, revealed by the ROS staining assay. The increase in osteogenic maturation with SeNPs was gradually investigated by expression of osteogenic genes at 3 and 7 days, Alkaline phosphatase activity staining at 14 days, and Alizarin red S staining at 28 days. Therefore, the role of SeNPs in regulating ROS and their therapeutic effects on the differentiation of MC3T3-E1 cells were determined, leading to possible applications for bone treatment.
Collapse
|
5
|
Shen J, Wang R, Wang Q, Zhang M, Liu C, Tao Z, Su G. The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development. Aging (Albany NY) 2020; 13:411-423. [PMID: 33290262 PMCID: PMC7835069 DOI: 10.18632/aging.202146] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Accepted: 10/01/2020] [Indexed: 11/25/2022]
Abstract
As the first clinical proteasome inhibitor, Bortezomib (BTZ) has been reported to improve the outcome of lymphoma. However, due to the unstable property, low bioavailability, and hydrophobic properties of BTZ, it is needed to develop effective drug delivery systems to deliver BTZ into targeted cells or organs. Here we developed a bortezomib (BTZ)-loaded HMSNs (BTZ@HMSNs) system, which can sustain the release of BTZ in targeted tissues. In vitro assays showed that BTZ@HMSNs limited cell proliferation and augmented apoptosis of lymphoma SNK-1 cells. Moreover, BTZ@HMSNs significantly diminished migration and invasion of SNK-1 cells as compared with BTZ. In contrast to the upregulation of SHP-1, BTZ@HMSNs decreased the mRNA levels of c-Kit, NF-κB, and JAK1, which elicit oncogenic role in lymphoma development. Importantly, lymphoma mice model showed that BTZ@HMSNs significantly activated p53 signaling and reduced tumor volume and weight compared with free BTZ. Our data thus demonstrate that BTZ@HMSNs manifests improved tumor-suppressing effect in vitro and in vivo compared to free BTZ. We believe that HMSNs is a promising strategy for delivering therapeutic agents for cancer treatment.
Collapse
Affiliation(s)
- Jie Shen
- Department of Hematology, Centre Hospital of Cangzhou, Cangzhou, Hebei Province, China
| | - Ruihuan Wang
- Department of Hematology, Centre Hospital of Cangzhou, Cangzhou, Hebei Province, China
| | - Qing Wang
- Department of Hematology, Centre Hospital of Cangzhou, Cangzhou, Hebei Province, China
| | - Minjuan Zhang
- Department of Hematology, Centre Hospital of Cangzhou, Cangzhou, Hebei Province, China
| | - Chunyan Liu
- Department of Hematology, Centre Hospital of Cangzhou, Cangzhou, Hebei Province, China
| | - Zhenxia Tao
- Department of Central Laboratory, Centre Hospital of Cangzhou, Cangzhou, Hebei Province, China
| | - Guohong Su
- Department of Hematology, Centre Hospital of Cangzhou, Cangzhou, Hebei Province, China
| |
Collapse
|
6
|
Yu Z, Li Q, Wang J, Yu Y, Wang Y, Zhou Q, Li P. Reactive Oxygen Species-Related Nanoparticle Toxicity in the Biomedical Field. NANOSCALE RESEARCH LETTERS 2020; 15:115. [PMID: 32436107 PMCID: PMC7239959 DOI: 10.1186/s11671-020-03344-7] [Citation(s) in RCA: 253] [Impact Index Per Article: 63.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Accepted: 05/10/2020] [Indexed: 05/19/2023]
Abstract
The unique physicochemical characteristics of nanoparticles have recently gained increasing attention in a diverse set of applications, particularly in the biomedical field. However, concerns about the potential toxicological effects of nanoparticles remain, as they have a higher tendency to generate excessive amounts of reactive oxygen species (ROS). Due to the strong oxidation potential, the excess ROS induced by nanoparticles can result in the damage of biomolecules and organelle structures and lead to protein oxidative carbonylation, lipid peroxidation, DNA/RNA breakage, and membrane structure destruction, which further cause necrosis, apoptosis, or even mutagenesis. This review aims to give a summary of the mechanisms and responsible for ROS generation by nanoparticles at the cellular level and provide insights into the mechanics of ROS-mediated biotoxicity. We summarize the literature on nanoparticle toxicity and suggest strategies to optimize nanoparticles for biomedical applications.
Collapse
Affiliation(s)
- Zhongjie Yu
- Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266021, China
- School of Basic Medicine, Qingdao University, Qingdao, 266071, China
| | - Qi Li
- Department of Emergency Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China
| | - Jing Wang
- Oral Research Center, Qingdao Municipal Hospital, Qingdao, 266011, China
| | - Yali Yu
- Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266021, China
| | - Yin Wang
- Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266021, China
| | - Qihui Zhou
- Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266021, China.
- Center for Stomatology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
| | - Peifeng Li
- Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266021, China.
| |
Collapse
|
7
|
Zhang C, Wang X, Cheng R, Zhong Z. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo. Biomacromolecules 2020; 21:2049-2059. [DOI: 10.1021/acs.biomac.9b01790] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Changjiang Zhang
- Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, People’s Republic of China
| | - Xiuxiu Wang
- Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, People’s Republic of China
| | - Ru Cheng
- Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, People’s Republic of China
| | - Zhiyuan Zhong
- Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, People’s Republic of China
| |
Collapse
|